Toby Capstick

Dr. Toby Capstick

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2024 in Clinical Drug Investigation
Verified
Journal Article
Open access
PDF file
TCToby Capstick
Toby Capstick
SGSanjay Gudimetla
Sanjay Gudimetla
DHDavid S. Harris
David S. Harris
RMRachel Malone
Rachel Malone
OUOmar S. Usmani
Omar S. Usmani
The selection of an inhaler device is a key component of respiratory disease management. However, there is a lack of clarity surrounding inhaler resistance and how it impacts inhaler selection. The most common inhaler types are dry powder inhalers (DPIs) that have internal resistance and pressurised metered dose inhalers (pMDIs) that use propellants to deliver the drug dose to the airways. Inhaler resistance varies across the DPIs available on the market, depending largely on the design geometry of the device but also partially on formulation parameters. Factors influencing inhaler choice include measures such as flow rate or pressure drop as well as inhaler technique and patient preference, both of which can lead to improved adherence and outcomes. For optimal disease outcomes, device selection should be individualised, inhaler technique optimised and patient preference considered. By addressing the common clinically relevant questions, this paper aims to demystify how DPI resistance should guide the selection of the right device for the right patient.

25 January 2024 in British Journal of General Practice
Verified
Journal Article
Open access
PDF file
MLMark L Levy
Mark L Levy
RBRichard Beasley
Richard Beasley
BBBev Bostock
Bev Bostock
TCToby Capstick
Toby Capstick
MCMichael G Crooks
Michael G Crooks
ABAndrew Bush
Andrew Bush
Resistance to changing clinical practice in response to scientific evidence is common. Complacency with asthma, and the entrenched overprescribing and overreliance on short-acting β2-agonist bronchodilators (SABAs) in asthma, persists in many parts of the world, including in the UK.1–4 Despite the known morbidity and mortality risks associated with regular and/or excessive use of SABAs, most countries have failed to implement the alternative evidence-based, anti-inflammatory reliever treatment (AIR), as recommended by the Global Initiative for Asthma (GINA) as a better and simpler way to manage asthma (Figure 1).5 This commentary, using the UK as an exemplar, aims to galvanise these countries to adopt an evidence-based and more effective approach to the management of asthma to reduce the risk of severe attacks.

1 October 2021 in Respiratory Medicine
Verified
Journal Article
Closed access
TCToby Capstick
Toby Capstick
NANooria F. Azeez
Nooria F. Azeez
GDGary Deakin
Gary Deakin
AGAshleigh Goddard
Ashleigh Goddard
DGDawn Goddard
Dawn Goddard
ICIan J. Clifton
Ian J. Clifton

25 July 2024 in British Journal of General Practice
Verified
Journal Article
Open access
PDF file
MLMark L Levy
Mark L Levy
TCToby Capstick
Toby Capstick
TAThomas Antalffy
Thomas Antalffy
Asthma management is changing, and the preferred option (track 1) recommended by the Global Initiative for Asthma (GINA) is that all people with asthma should be prescribed an inhaled corticosteroid either as needed in mild asthma or regularly for those with more severe asthma.1 Short acting β2-agonist bronchodilators (SABAs) certainly have an essential role in the management of acute asthma attacks, but their regular use in the chronic management of asthma has recently been highlighted as having potentially dangerous adverse clinical effects, especially when used without inhaled corticosteroids.1,2 The association between excess prescriptions of SABAs and increased asthma attacks, healthcare utilisation, and deaths has been known for decades,3,4 and illustrated so clearly in the SABINA studies5,6 and the UK National Review of Asthma Deaths (NRAD).7 Furthermore, it is 30 years since Suissa et al3,4 demonstrated the association between asthma death and one or more SABA inhaler prescriptions a month with a concomitant reduction in mortality when inhaled corticosteroids (ICS) were used.

3 June 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
AWAntony Wright
Antony Wright
HVHelene Vioix
Helene Vioix
SSShamika de Silva
Shamika de Silva
SLSue Langham
Sue Langham
JCJennifer Cook
Jennifer Cook
JQJennifer Kathleen Quint
Jennifer Kathleen Quint
Objectives The objective of this study was to model the clinical and economic impact of adapting current clinical practice in the management of patients with chronic obstructive pulmonary disease (COPD) to treatment according to national and international guideline recommendations. Design Treatment mapping was undertaken to hypothetically redistribute patients from current clinical practice, representing actual prescribing patterns in the UK, to an alternative recommendation-based treatment scenario, representing prescribing in accordance with either National Institute for Health and Care Excellence (NICE) guidance [NG115] or Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020 strategy. Setting Primary care practices in the UK (1-year time horizon). Participants Adults with COPD undergoing long-acting inhaler maintenance therapy in the UK (N=1 067,531). Interventions Inhaler maintenance therapy. Outcome measures Costs and clinical outcomes (type of treatment, rates of moderate and/or severe exacerbations, and mild-to-moderate and/or severe pneumonia events) were modelled for the two alternative pathways. Results Compared with current clinical practice, treating patients according to NICE guidance resulted in an estimated annual reduction in expenditure of £46.9 million, and an estimated annual reduction in expenditure of over £43.7 million when patients were treated according to GOLD 2020 strategy. Total cost savings of up to 8% annually could be achieved by treatment of patients according to either of these recommendations. Cost savings arose from a reduction in the rates of pneumonia, with an associated decrease in costs associated with antibiotic use and hospitalisation. Savings were achieved overall despite a small increase in the rate of exacerbations due to the redistribution of certain patients currently undergoing triple inhaled therapy to therapies not containing inhaled corticosteroids. Conclusion Redistribution of patients with COPD from current clinical practice to treatment according to published recommendations would provide substantial cost savings over the first year.

1 October 2021 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
TCToby Capstick
Toby Capstick
NHNicholas Hopkinson
Nicholas Hopkinson
The takeover of Vectura, a healthcare company specialising in inhaled medication, by Philip Morris International raises serious ethical concerns. The European Respiratory Society notes that “health professionals will avoid prescribing drugs from any company that enriches the tobacco industry due to the ethical implications”. People with chronic obstructive pulmonary disease (COPD) and asthma will also be reluctant to use medications which profit a company that is estimated to kill at least one million people every year. We discuss the practicalities involved in switching people with lung disease to inhaled medications that are not tobacco industry linked. Potential alternative inhaled medications are set out, which are likely to be equally effective for most patients. A consideration of beneficence, non-maleficence, autonomy, and distributive justice demonstrates strong ethical reasons to support switching away from the prescription of tobacco industry linked products.